Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04317105
Title Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Copanlisib + Ipilimumab + Nivolumab

Copanlisib + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST